Table 1.
Baseline characteristics of included articles.
| # | Author | Country | Study Design | Sample Size: (Control; Cases) |
Median Age in Years | Female (%) | |
|---|---|---|---|---|---|---|---|
| Cases | Control | ||||||
| 1 | Altuntaş, et al. (2021) [19] | Turkey | Prospective case—control study | (132; 131) | 39 ± 10 | 41 ± 9 | 89 |
| 2 | Pilla, et al. (2020) [41] | India | Prospective case—control study | (100; 100) | 38 | 40 | - |
| 3 | Varshney, et al. (2018) [42] | India | Prospective case—control study | (50; 100) | 32.14 ± 3.11 | 35.60 ± 4.57 | 54 |
| 4 | Madhu, et al. (2016) [15] | India | Prospective case—control study | (60; 62) | 31.4 ± 11.3 | 32.5 ± 10.1 | Case = 87.1 Control = 85 |
| 5 | Coban, et al. (2004) [32] | Turkey | Prospective case—control study | (50; 50) | 35.7 ± 11.9 | 60 | |
| 6 | Gram-Hansen, et al. (1990) [31] | Denmark | Prospective case—control study | (10; 10) | 52 ± 13.5 | 60 ± 5.5 | - |
| 7 | Aydın, et al. (2022) [43] | Turkey | Prospective cohort study | (0; 146) | 45 ± 2.5 | 82.1 | |
| 8 | El-agouza, et al. (2002) [33] | Egypt | Prospective cohort study | (0; 51) | University school age | - | |
| 9 | Mustafa, et al. (2021) [44] | Pakistan | Quasi-experimental trial | (0; 182) | 54.84 ± 8.69 | 45 | |
| 10 | Nasli-Esfahani, et al. (2017) [45] | Iran | Randomized clinical trial | (45; 45) | 51.47 ± 7.07 | 52 ± 7.35 | 70 |